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Sumlorlslry 
Chagas' disease results from the infection of the protozoan parasite Tr,/panosoraa cruzi and affects 
several million people in South America. Several alterations of the immune response have been 
described in this disease, such as severe immunosuppression  of  both cellular and humoral responses 
and massive polyclonal stimulation with the generation of autoantibodies crossreacting with host 
cells and tissues. We have obtained monodonal antibodies (mAbs) from T. cruzi-infected mice 
that recognized a 50/55-kD antigen (GP50/55) on the T. cruzi  membrane, but not in other 
parasites of the family Trypanosomatidae. One of these GPS0/55-specific  mAbs (C10) crossreacts 
with a 28-kD antigen (p28) expressed on the membrane of >85% of activated mouse T  and 
B lymphocytes, after in vitro activation with concanavalin A, Salmonella typhosa lipopolysaccharide, 
phorbol dibutyrate ester, or antigen, and on several murine T and B lymphocyte cell lines. Human 
T  and B lymphocytes also express upon activation with phytohemagglutinin or Staphylococcus 
aureus Cowan I (SAC) a similar antigen recognized by mAb C10, although in a lower proportion 
of ceils (30-40%).  Furthermore, this mAb was able to suppress mouse and human T  and B 
cell proliferation to any of those stimuli. In addition, sera from chagasic patients and T. cruz/-infected 
mice, but not from control patients or littermates, contain antibodies that recognize a similar 
p28 antigen on B lymphocytes. Furthermore, the immunoglobulin fractions of some chagasic 
sera also suppress the proliferation of human T  lymphocytes. These results suggest a possible 
pathological  role  of  autoantibodies  as  an  alternative  mechanism  for  T.  cruzi-associated 
immunosuppression. 
T 
rypanosoraa cruzi is the causal agent of the Chagas' dis- 
ease, which affects several million people in Central and 
South America (1). This protozoan parasite has a complex 
life cycle and exists in at least three morphologically distinct 
forms: infective (metacyclic or blood trypomastigotes), in- 
sect  borne  (epimastigotes),  and  intracdlular  replicative 
(amastigotes), which grows and replicates inside a variety of 
mammalian cells (1). 
From a clinical point of view, the T cruzi infections pro- 
ceed in two phases.  In the acute phase,  circulating blood 
trypomastigotes are observed and there is a local inflamma- 
tion at the sites of infection (1). During the chronic phase, 
circulating parasites cannot be observed by inspection of blood 
but progressive tissue damage occurs involving the esophagus, 
colon, and heart (1). 
An autoimmune mechanism in the pathogenesis of human 
and experimental models of chronic Chagas' disease has been 
proposed (2, 3), but the exact role that this mechanism plays 
in disease production is not clear. A massive polyclonal acti- 
vation ofT and B lymphocytes (4) with an increased produc- 
tion of autoantibodies (5), together with a severe  immunosup- 
pression of the humoral and cellular responses (6) have been 
described in the acute phase of Chagas' disease, although the 
importance of those phenomena on the pathology of the dis- 
ease is still poorly understood (6,  7). 
On the other hand, there are many examples of antibodies 
from sera of T. cruzi-infected  patients or animals that have 
been shown to react with host nervous and cardiac tissue an- 
tigens (8-15).  In addition, T cells that are crossreactive with 
cardiac or nerve cells have been also found in mice with ex- 
perimental Chagas' disease (16, 17), which can transfer the 
tissue pathology to naive animals (16). This has led to the 
hypothesis that T, cruzi has crossreactive antigens that mimic 
host molecules, which are responsible for the tissue damage 
associated with the chronic phase of Chagas' disease (2, 3), 
when virtual absence of parasites exists. The origin of the 
autoimmunity in Chagas' disease is not yet understood but 
it is likely that the polyclonal stimulation caused by the para- 
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for the origin of this apparent breakdown of stir-tolerance 
(18). Thus, it has been proposed that the combined effects 
of the polydonal stimulation and the chronic presence of  cross- 
reactive antigens give rise to the autoimmune pathology of 
Chagas' disease (18). Therefore, it is important to characteri~ 
these crossreactive  antigens in order to get a clearer under- 
standing of their function in the etiology of this disease in 
the chronic phase. 
In a previous work (19), we described four mAbs that recog- 
nize a 50/55-kD antigen (GP50/55) on T. cruzi membrane. 
We describe in this manuscript that one of these GP50/55- 
specific mAbs crossreacts with an activation antigen present 
on T  and B lymphocyte membranes and is able to suppress 
polyclonal T  and B proliferation. Furthermore, antibodies 
with similar specificity are present in the sera from chagasic 
patients and from infected mice. This is the first description 
of a T, cruzi-specific mAb that recognizes an activation an- 
tigen of T and B lymphocytes, and our results suggest a pos- 
sible pathological role of  autoantibodies as an alternative mech- 
anism for T  cruzi-assodated  immunosuppression. 
Materiah and Methods 
Parasites and Cell Lines,  The strain of T cruzi used was origi- 
nally obtained from a patient with Chagas' disease  in the Instituto 
Nacional de la Salnd (Madrid, Spain). It w~s cloned and named 
strain G. Promastigote forms of Leishmania mexicana were obtained 
from Dr. Luis  Rivas (Instituto de Investigaciones  Bio16gicas,  Madrid, 
Spain). T cruzi epimastigotes and L. mexicana promastigotes para- 
sites were grown  in liver infusion tryptose medium (20) with 10% 
of FCS (Flow Laboratories, Inc., McLean, "CA) at 27~ 
The murine ~1" hybridoma DO-11.10 (21) and the routine B plas- 
macytoma P3X63Ag8 and Sp2/0+Ag14 (Sp2/0 +) (22) cell lines 
were cultured in complete RPMI 1640 (Gibeo Laboratories, Grand 
Island, NY) containing 10% FCS. The human B lymphoblastomas 
Daudi and JY, the human B hybridomas Sp0/0 and HMA.A (a 
gift from Dr. F. Gamb6n, Hospital Puerta de Hierro, Madrid), the 
murine  lymphoma  Yac-1, the  routine  helper  T  cell clone 
C1.Ly1+2-/9  (D9V) (23), and the human  T  lymphoblastoma 
CEM cell lines  were routinely grown in the same  media. The human 
T lymphoblastomas  Jurkat and MOLT-4, the human monocyte cell 
line U-937, the murine macrophage-like cell line J774-G8 derived 
from murine reticuhm cell  sarcoma, the routine phsmacytoma  P815, 
the murine neuroblastomas N2A and Nl15, the murine fibroblast 
b929, and the human carcinoma HeLa were cultured in DMEM 
(Gibco Laboratories) containing 10% FCS. The murine IL-2-de- 
pendent T cell line, CTLb2, was maintained in continuous cul- 
ture in RPMI 1640 supplemented  with 5% FCS, 5 x  10 -s 2-ME, 
and 2% conditioned medium from Con A-treated routine spleen 
T lymphocytes. The cultures were maintained at 37~  in a hu- 
midified atmosphere containing 5% COz. 
Antibodies.  The mAb C10 hybridoma was obtained in our lab- 
oratory from T. cmzi-infected BALB/c mice (19). The mice were 
infected (10  +  parasites/mouse) with a mixture of morphologies of 
live T. cruzi (50% epimastigotes, 30% trypomastigotes, and 20% 
amastigotes) with the immunization protocol described previously 
(19). The mAb M1/9.3.4.HL.2  anti-mouse CD45 and the mAb 
34.1.2 anti-H-2  a were obtained from Dr. J. M. ILojo (Centro de 
Investigaciones Biolrgicas, Madrid, Spain), anti-h  a antibodies  were 
purchased from Becton Dickinson & Co. (Erembodegem-Aalst,  Bd- 
gium). The irrelevant mouse IgG1 (P3) was obtained from the hy- 
bridoma P3X63AgS. The rabbit F(ab')2 anti-mouse Ig-FITC and 
the goat anti-rat Ig-FITC antibodies  were purchased from Southern 
Biotechnology (Birmingham, AL). 
The mAbs C10 and I>3 were purified  by affinity  chromatography 
with protein A-Sepharose CL4B (Sigma Chemical Co., St. Louis, 
MO), and they were biotinylated with N-hydroxysuccinimido  bi- 
otin (Sigma Chemical Co.). 
Human  chagasic sera were obtained  from  Argentina  and 
Colombia and were a gift from Drs. C. Alonso, J. M. Requena 
(Centro de Biologia Molecular, Madrid, Spain), and M. L6pez (In- 
stituto Lrpez-Neyra, Granada, Spain). The Ig fraction was purified 
by affinity  chromatography with anti-human Ig (Nordic, Tilburg, 
UK) covalently coupled to protein A-Sepharose CL4B by using 
dimethyl-dipimelimidate as crosslinker agent. 
Cytofluorimetry Analysis.  Cells  (1-2 x  10  s) or parasites (1-2 x 
10  +) were centrifuged three times in PBS with 2% BSA and 0.1% 
sodium azide. They were subsequently incubated with 50/~g/ml 
of biotin-labeled mAb C10, or biotin-labeled control mAb P3, or 
nonlabeled antibodies  diluted in the same  buffer, for 30 rain at 4~ 
Cells or parasites were washed in the above buffer and incubated 
again with 50/~1 of streptavidin-PE or 50/zl rabbit anti-mouse 
F(ab')z Ig-FITC  or  goat  anti-rat Ig-FITC  (Southern  Biotech- 
nology) diluted in the same buffer, for 30 rain at 4~  in the dark. 
After three rinses, the parasites or ceils were resuspended in the 
same buffer containing 1% paraformaldehyde,  and the fluorescence 
was analyzed  in an EPICS cytofluorimeter  (Coulter Scientific,  Har- 
peden, UK). Detailed combination of reagents for the doubh-color 
staining is described in the legend of Fig. 3. 
Immunoprecipitations.  Parasites  (2  x  10  s epimastigotes)  or cells 
(2  x  107) were labeled with 12sI by the lactoperoxidase method 
(19). The immunoprecipitations of T. cruzi antigens were carried 
out using preformed protein A-Sepharose Cb4B (Sigma Chemical 
Co.) antibodies complexes  as described (19). For immunoprecipita- 
tion from labeled murine cells, these were divided in two aliquots 
of 2 ml in PBS, and 50-100/zg of purified mAb C10 or irrelevant 
mouse IgG1 mAb were added. The samples were incubated for 
2 h at 4~  Cells were washed three times with PBS and were 
disrupted in 1 ml of lysis buffer containing 1% NP-40 (19). The 
immunoprecipitation  of  cell antigen was carried  out as described  (19). 
Proliferation Assays.  BALB/c  mice were immunized intraperi- 
toneally with a T. cruzi extract obtained from 107 epimastigotes 
per mouse in PBS mixed with CFA at day 0. At day 28, mice were 
immunized in the same way but substituting CFA for IFA. At the 
day 42, mice were finally  injected intraperitoneally  with the T. cruzi 
extract without adjuvants. Mice were killed by COs inhalation 
15 d after the last immunization. Spleens were removed, the RBC 
were eliminated by hypotonic shock, and the spleen cells  were acti- 
vated in vitro with Con A, phorbol dibutyrate ester (PDBu),  ~ 
LPS, or parasite lysates  at the indicated concentrations in the pres- 
ence of different concentrations of antibodies. 
Human PBL were obtained from heparinized venous blood of 
healthy volunteers by Ficoll-Hypaque centrifugation as described 
(24). Human T cells were activated with different concentrations 
of PHA (Sigma Chemical  Co.) in the presence of the indicated con- 
centrations of the antibodies. Human B cells were obtained from 
human tonsils of children 4-10 yr old, and the cells were activated 
with Staphylococcus aureus Cowan I (SAC) (Calbiochem-Behring 
Corp., San Diego, CA) as described (25). 
1 Abbreviation used in this paper: PDBu, phorbol dibutyrate ester. 
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microtiter plates (Flow Laboratories,  Inc.) containing 100 #l/weU 
with 1-5  x  10  s cells in complete RPMI 1640 with 10% FCS and 
5  x  10 -s M 2-ME. The cultures were maintained at 37~  in a 
humidified atmosphere containing 5%  CO2 for 24-96  h.  Cell 
proliferation was estimated by the amount of [3H]thymidine (New 
England Nuclear, Boston, MA) incorporated during the last 4-16 h 
of culture. Cells were harvested, and the radioactivity incorporated 
into DNA was measured in a liquid scintillation counter. 
Results 
The 77. cruzi-specific mAb CIO Is Crossreactive with an Acti- 
vation Antigen Present on T and B Lymphocytes.  We have ob- 
tained  mAbs  from  T  cruzi-infected  mice with  the aim of 
searching for those that were crossreactive with host cells. 
For this  purpose,  BALB/c mice were infected with  the  T. 
cruzi G strain and hybridomas were first selected by thdr ability 
to secrete antibodies that bind specifically to intact parasites 
(19). To search for autoreactivity, the binding of these mAbs 
against a pand of transformed mouse call lines from distinct 
tissue origins was tested by cytofluorimetry analysis. One of 
these mAbs, termed mAb C10, strongly reacted with 99% 
of the intact T. cruzi epimastigotes (Fig. 1). mAb C10 reacted 
with  all  the  morphological  forms  of the  parasite:  trypo- 
mastigotes,  amastigotes, and epimastigotes (19). This mAb 
was T. cruzi specific since it did not react with other closely 
related protozoa belonging  to the  Trypanosomatidae family, 
such as L. mexicana (Fig.  1), T  brucei, and L. infantum  (data 
not shown). Among the cell lines tested, the call membrane 
of some T  cells, such as DO-11.10  (21), and of B cell plas- 
macytomas, such as SP2/0 + (22), was strongly stained with 
mAb C10 (Fig. 1). Cell lines from origins other than T  and 
B lymphocyte lineage were negative. T or B cell lines of human 
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Figure 1.  Reactivity of mAb C10 with T cruzi and mouse lymphocyte 
cell lines. For the cytofluorimetry analysis, cells (1-2  x  10  s) or parasites 
(I-2  x  106) were washed as described in Materials and Methods. Then, 
they were stained with biotin-labeled mAb C10 or biotin-labeled  control 
mouse IgG1 for 30 rain at 4~  Cells or parasites were incubated with 
streptavidin-PE diluted 1/300 for 30 min at 4~  in the dark. The fluores- 
cence was analyzed in an EPICS cytofluorimeter. The histograms repre- 
sent the number of  cells versus the logarithm of the fluorescence  intensity. 
The white and black profiles represent the fluorescence  staining obtained 
with the control P3 mAb or mAb C10, respectively.  The percent of posi- 
tive cells and the cells  for each case  are shown inside the corresponding  panel. 
Table  1.  mAb C10 Expression on Several Cell Lines 
Cell lineage  Origin  Percent positive cells 
B cells: 
Sp2/0 + Ag14  Mouse  99.3 
P3X63 Ag8  Mouse  69.7 
Daudi  Human  5.0 
Sp0/0  Human  2.3 
JY  Human  3.5 
HMA.A  Human  6.8 
T  cells: 
DO- 11.10  Mouse  98.0 
D9V  Mouse  0.0 
CTLL-2  Mouse  0.0 
Yac-1  Mouse  1.4 
Jurkat  Human  1.3 
MOLT-4  Human  2.6 
CEM  Human  3.7 
Monocytic cells: 
U937  Human  3.9 
Neuronal cells: 
N2A  Mouse  2.0 
Nl15  Mouse  4.0 
Epithelial cells: 
Hela $3  Human  0.0 
L929  Mouse  0.0 
Binding of mAb C10 to cell lines was assayed by flow cytometry. Calls 
(1-2  x  10  s) were washed as described in Materials and Methods. Then, 
they were stained with biotin-labeled  mAb C10 or biotin-hbded control 
mouse IgG1, for 30 rain at 4~  Cells were incubated with streptavidin- 
PE diluted 1/300 for 30 rain at 4~  in the dark. The fluorescence  was 
analyzed in an EPICS cytofluorimeter.  The percent of positive cells shown 
was calculated by subtracting the binding of the irrelevant control. 
origin were negative (Table 1). This result prompted us to 
test  the reactivity of the mAb  C10 with normal  T  and B 
lymphocytes from BALB/c mouse spleen. As shown in the 
Fig. 2, a very small percent (6-13%) of cells in a normal spleen 
were positive for this antibody. By contrast, this percentage 
rose to 85%  or more after 96 h  of in vitro activation with 
PDBu, with the T  cell mitogen Con A, or with the B cell 
mitogen Salmonella typhosa LPS (Fig. 2). The binding of mAb 
C10 to the membrane of activated mouse lymphocytes was 
not due to the recognition of the Con A or LPS used in the 
stimulation, because the crossreactive mAb C10 antigen was 
also induced by phorbol ester stimulation, and Con A or LPS 
were unable to affect the mAb C10 binding to either DO- 
10.11  or  Sp2/0 +  cells  (data  not  shown).  The binding  of 
mAb C10 to T  and B cells was not due to the Fc receptor 
since binding of isotype-matched irrelevant antibodies was 
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Figure 2.  Reactivity of mAb 
C10  with  mouse  spleen  cells. 
Spleen cells from normal BALB/c 
mice,  obtained  as  described  in 
Materials and Methods, were ac- 
tivated in vitro by incubating with 
PDBu  (:20 ng/ml),  Con A  (1.5 
/.tg/ml), or Salraonell~ t~hosa LPS 
(50  /~g/ml) in complete RPMI 
1640 containing 10%  FCS. The 
cultures were maintained at 37~ 
in a humidified atmosphere con- 
taining 5% CO2, for 96 h. The 
top panel shows the stain pattern 
of resting spleen cells with the 
mAb C10,  and the other histo- 
grams show the stain pattern of 
activated  spleen  cells  with  the 
different  stimuli used.  The cells 
were stained and analyzed as de- 
scribed in Fig. 1. The histograms 
represent  the  number  of  cells 
versus the logarithm of the fluo- 
rescence intensity. The white and black profiles represent the fluorescence 
staining obtained with the control P3 mAb or mAb C10,  respectively. 
The percent of positive cells is shown inside the corresponding panel. 
negative. Therefore, the lymphocyte antigen recognized by 
mAb C10 is present in both activated mouse B and T cells. 
By double-color cytofluorimetry analysis,  the mAb C10 
antigen was first dearly detected on the membrane of Ig + 
B mouse cells after 48 h of LPS activation. This expression 
rose strongly after 72 h and it was maximal 96-120 h after 
the addition of the stimulus (Fig. 3). These results also indi- 
cated that all Ig + cells expressed mAb C10 antigen. Similar 
results in the kinetic of mAb C10 expression were obtained 
after PDBu or Con A  stimulation (data not shown). 
Despite the lack of reactivity of human T and B cell lines 
with mAb C10, we tested the effect on normal human PBL 
stimulated with T  and B cell mitogens. As seen in Fig.  4, 
resting human lymphocytes were weakly stained with the 
antibody. However, after 48 h of in vitro activation with PHA 
or SAC, 30-40%  of both T  and B cells were positive,  and 
this percent, in contrast to the mouse system, did not in- 
crease with longer stimulation times. These activated cells 
were strongly positive for other activation antigen markers, 
such as 4F2 or CD25, 65-85%, (data not shown), therefore 
discarding inefficient activation as the cause of the lower per- 
cent observed with human lymphocytes. Interestingly, mAb 
C10 antigen expression on the membrane of activated human 
T  cells was stronger than activated human B cells. 
mAb C10 recognized a GP50/55 T. cruzi glycoprotein that 
is linked to the membrane by a glycosyl-phosphatidylinositol 
anchor (19). This antigen can be immunoprecipitated by mAb 
C10 from tzsI-labeled  T. cruzi lysates (Fig.  5). By contrast, 
a faint but detectable band *28 kD was specifically immu- 
noprecipitated by mAb C10 from intact Sp2/0 + (Fig.  5) or 
DO-11.10 (data not shown) |25I-labeled cells. Similar results 
were obtained under reducing or nonreducing conditions (data 
not shown). 
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Figure 3.  mAb C10 antigen and Ig expression on activated mouse B 
lymphocytes. B lymphocytes were obtained by lysis ofT cells by incubating 
with anti-mouse T cell serum and C (Cedadane, Hornby, Ontario, Canada). 
The cells were activated by incubation with LPS (50 ~g/ml) for several 
hours (0, 24, 48, 72, 96, or 120 h). Cells were first incubated with rabbit 
F(ab')2  anti-mouse  Ig-FITC  (x-axis).  Residual  binding  sites  and  Fc 
receptors were saturated by incubating with 100 ~g/ml mouse IgG. After 
washing, cells were further stained with biotin-cunjugated mAb C10. PE- 
conjugated streptavidin was added at the end C-axis). The percent of cells 
with positive or negative fluorescence for each group is shown below each 
panel.  Similar results have been observed in two other independent ex- 
periments. 
mAb C101s Able to lnhibit T and B CelI Proliferation.  Since 
the antigen detected by mAb C10 was present in almost 90% 
of activated mouse spleen cells, we tested the functional effects 
of mAb C10 on T and B cell activation. Concentrations of 
purified antibody as low as 0.5 #g/ml were able to induce 
maximum inhibition of the mouse spleen cell proliferation 
to Con A  as measured by incorporation of [3H]thymidine 
into DNA 72 h later (Fig. 6). Spleen cells from BALB/c mice 
previously immunized with T. cruzi, as described in Materials 
and Methods, were activated in vitro with either Con A, 
LPS, PDBu, T cruzi, or L. mexicana extracts. As seen in Fig. 
7, these immune spleen cells proliferated in response to Con 
A, LPS, PDBu, or the appropriate antigen (T. cruzi extracts), 
but not to L.  mexicana extracts. When purified mAb C10 
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Figm'e 4.  mAb C10 antigen expression on activated human T and B 
lymphocyt~ Human T and B cells were obtained as described in Materials 
and Methods and we~ activated  in vitro by incubating with PHA (2/~/ml) 
or Staf~/oc~cus  morus Cowan I (1 ttg/ml) in complete RPMI 1640  con- 
taining 10% FCS. The cultures were maintained  at 37~  in a humidified 
atmosphere containing  5% CO2, for 48 h. The cells  weee  stained and ana- 
lyzed as described in Fig. 1. The staining  pattern of resting PBL or tonsil 
lymphocytes is shown in  a and b, respectively; c and d show the staining 
of PHA-activated PBL and SACI-activated tonsil lymphocytes. The white 
and black profiles represent the fluorescence staining obtained with the 
control P3 mAb or mAb C10, respectively.  The percent ofmAb C10-pofi- 
rive cells and the mean fluorescence intensity  for each cell popuhtion are 
shown inside the corresponding  panel. 
(1/~g/ml) was added to the cultures, a similar inhibition of 
the proliferation to all  stimuli was observed. 
The kinetic of this proliferative inhibition by the mAb C10 
correlated with the kinetic of appearance on the cell mem- 
brane of the mAb C10 crossreactive antigen in those immune 
spleen cells  (Fig.  8).  The inhibition of T  cell proliferation 
to Con A by mAb C10 was not observed during the first 
24 h of culture. It was first detected after 48 h and was max- 
imal after 72 or 96 h (Fig.  8). Similar results were obtained 
with the stimulation of B calls with LPS (data not shown). 
Antibodies with Similar Specificity to mAb C10 Exist in Human 
Ckagasic Sera and in T. cruzi-infected Mice Sera.  To test the 
presence of antibodies with similar antigenic specificity to 
mAb C10 in the sera of chagasic patients and infected mice, 
inhibition experiments of the binding of biotinylated mAb 
C10 to intact parasites  and cells were carried out.  As seen 
in Fig. 9 and Table 2, sen of T. cruz/-infected mice and humans 
were able to block specifically mAb C10 binding both to lym- 
phocytes and to T. cruz/epimastigotes,  detected by cytofluorim- 
etry analysis.  Furthermore, the binding of other antibodies 
to different surface molecules such as mAb M1/9.3.4.HL.2 
(anti-murine CD45) (Fig. 9 and Table 2), anti-H-2  a or anti- 
Iad  (data  not  shown)  on  lymphocyte  membranes  was 
unaffected. All sera from the chagasic patients tested (5/5) 
were able to, specifically and significantly, block the binding 
of mAb C10 to T. cruzi and Sp2/0 § independently of their 
titer of antibodies against T. crv,  zi. Sera from human controls 
of the same area were negative (2/2). Furthermore, sera from 
T. cruzi-immune mice were less effective than sera from in- 
fected mice in blocking mAb C10 binding, despite the fact 
that immune sera had 300 times higher anti-T, cruzi antibody 
titer (Table  2). 
Figure S.  Immunoprecipitation with  mAb C10  from  T. cntz/  and 
Sp2/0*. Irnmunolnecipitation from T. cruz/or from Sp2/0  + cells extracts: 
(C) with an irrelevant P3 mouse IgG1 mAb and (C10) with the mAb 
C10. Parasites (2  x  10  e eplm=,figotes) or celh (2  ￿  107) were labeled 
with nsI by the lactoperaxidase method and then lysed in 1%  NP-40. 
The immunoptecipitatiom  were carried out as described in Materials and 
Methods. The immunoprecipitated antigens were subjected to dectropho- 
resis on a 10-15% acrylamide/SDS gels. The molecular mass markers are 
indicated. 
To further confirm the specificity of the antibodies present 
in the chagasic sera, we purified the Ig fraction of the sera, 
and that fraction was tested in the proliferation of human 
PBL. mAb C10 was able to inhibit (40-50%) PHA-dependent 
prolifemion of human T  cells,  in a percent similar to the 
percent ofmAb C10-positive  lymphocytes (40%) among these 
activated cells (Fig.  10). Similarly, purified Igs from the sera 
of two chagasic patients, but Igs not from normal sera, also 
inhibited, in a dose-response manner, PHA proliferation (Fig. 
10). Of purified Igs from 14 chagasic sera  tested,  50%  of 
them had similar inhibition to the two shown in Fig.  10, 
whereas four were without effect and three were weakly in- 
hibitory (data not shown). 
Discussion 
It is likely that the combined effects of the polyclonal stim- 
ulation and the chronic presence of crossreactive antigens could 
account for the autoimmune pathology of Chagas' disease 
(18). To get a clearer understanding of the function of self- 
reactive antibodies in the etiology of this disease,  we have 
obtained mAbs from T. cmzi-infected mice with the aim of 
characterizing the relevant parasite antigens. 
Although several T. cruzi-specific antibodies that crossreact 
1477  Hern~ndez-Munain  et al. 120 
x 
eol 
~0 I 
.r 
\ 
rnab  CqO  (lag/rot) 
Q 
~0 
Figure 6  Dose-response  mh~- 
bmon of mAb C10 in the mouse  ~" 
spleen cell prohfenuon to Con A 
Normal spleen cells were acuvated 
m wtro w~th Con A (1 5 #g/ml) 
and incubated m presence of mAb 
C10 at the m&cated  concentra- 
uons  The  prohferat~on  assays 
were  earned  out  as  described 
Materials and Methods  The cul- 
tures were maintained at 37~  m 
a  huml&fied  atmosphere  con-  ~' 
taming 5% C02 for 72 h  Cell 
prohferauon was estmaated by the 
amount of [3H]thymxdme incor- 
porated dunng the last 4-16 h 
with molecules expressed  m  host cells have been described 
(8-15), and sera from chagaslc pauents have been shown that 
recogmze neurotransmltter  receptors  on lymphocytes  (26), 
the present  work ~s to our knowledge the first descnpuon 
of a mAb that crossreacts w~th an acuvauon anugen present 
m  human  and mouse T  and B  lymphocytes 
Our data also re&care that  ant,bo&es w~th slm,lar  reac- 
tw~ty to mAb C10 may ernst m the sera of infected m&vxd- 
uals  and animals  Ths  hypothem ~s supported by the fact 
that  (a) antlbo&es m chagas~c sera but not m control sera 
were able to block specifically  mAb  C10 binding,  both to 
lymphocytes and to T. cruz~ ep~masugotes  (Table 2)  It ~s very 
unhkely that the competmon for the binding of mAb C10 
to two &fferent molecules, GP50/55 m  T. cruz= and p28 on 
lymphocytes, by chagastc sera was due to stenc reasons since 
the binding of other surface molecules, such MHC anugens 
or CD45, htghly abundant  on the lymphocyte surface, were 
unaffected  Therefore, ~t is hkely that the Igs of the chagaslc 
sera contain anubodtes  of slmdar  speoficaty to mAb  C10, 
although it ~s very dff~cult to completely ascertain d the an- 
ubo&es m chagas~c sera recogmze or not the same epltope 
that  the mAb C10 recogmzes  (b) Ant~bo&es  m  some cha- 
gas~c sera but not m control sera were able to suppress human 
T  cell prohferatwe responses  as mAb C10 &d  Obv~ousl3r, 
ths mhbmon could be due to many other Igs with different 
spec~ficaues in those sera, since ~t ~s very difficult to prove 
beyond a reasonable  doubt that  the anubodxes  are bmdmg 
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Figure 8  Corrdataon between 
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pression of the mAb C10 anugen 
Normal mouse spleen cells were 
activated with Con A (1.5/~g/ml) 
in 96-weU m~eromer plates as de- 
scribed m the legend to Fig  5, m 
the presence of mAb C10 (@) or 
P3 (O)  After 24, 48, or 72 h of 
culture, the cells were  (.4) pulsed 
with pH]thymldme dunng the 
last 4 h to measure cell prohfera- 
uon or (B) stained with mAb C10 
as desmbed m the legend to Fig 
1  The  percent  of posture  and 
negauve  cells  for  each  case  is 
shown reside  the correspoodmg 
panel 
to the same  epltope that  mAb C10 does  The reason  that 
only 50% of the sera were inhibitory could be related to the 
&fferent  tlters  of Igs with mAb C10-hke reacuwty m  the 
&fferent sera. In general, the sera that rabbited T cell prohfer- 
auon were the ones that  had stronger mhlbiuons of mAb 
C10 binding to lymphocytes  Alternatively,  since it is known 
that there are at least two chmcal mamfestauons of the &s- 
ease, ~t ~s possible that ths is potenually related to our results 
Furthermore, although this inhibition was low, it correlated 
w~th the percent  of mAb C10-posmve  cells m  those acu- 
vated popuhuons, which also supported the nouon that the 
Igs of those sera were blocking prohferauon through mAb 
C10 binding. Taking all together, our data support the no- 
uon that anubo&es against p28 oust m cbagas~c pauents and 
mice and could contribute at least  m  part to the observed 
~mmunosuppress~on 
It ~s worth noting that the sera from T  cruzi-tmmune mlce 
were less effecuve than serum from infected mice m blocking 
mAb C10 binding, despite the fact that tmmune serum had 
300 umes higher anu-T cruz= anubody uter. This is m agree- 
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cated concentra~ons, m the presence 
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ment with the fact that only a small percent (1/4) of mAbs 
against GP 50/55 (19) are crossreactive with p28 (Hern~ndez- 
Munafn  et  al.,  unpublished  results).  Besides,  these  results 
confirm the importance of studying antibody repertoire from 
infected animals instead of from immunized animals.  It has 
been shown that a T. cruzi infection does not have the same 
effects  in  the  immune  system  as  an  exposition  to  dead 
microorganisms  (27).  Therefore,  our  results  confirm  that 
an active infection induces antibodies with a different reper- 
toire of antigenic specificities to those of classical immuni- 
zations. 
Our data suggest that T. cmzi presents antigens on its mem- 
brane that can induce crossreactive antibodies to the surface 
antigens of T  cruzi-activated lymphocytes during the infec- 
tion and inhibit their proliferation.  This phenomenon  is of 
particular interest in as much as the specific recognition  of 
lymphocyte membrane receptors by autoantibodies  may re- 
sult in modulation of immune response in Chagas' disease. 
It has been suggested that Chagas' disease may have an im- 
munological  basis  (2,  3,  6,  7).  Severe immunosuppression 
of the immune responses in the acute phase of the infection 
Figure 9.  Inhibition of mAb C10 or mAb M1/9.3.4.HL.2  (anti-mu- 
rine CD45) binding to T. cruzi or Sp2/0 + membrane by cytofluorimetry 
analysis. The assay was performed as described in the legend to Table 2. 
The histograms represent the number of cells versus the logarithm of the 
fluorescence intensity. The white profiles represent the staining with the 
irrelevant mAb. The percent of positive cells and the mean fluorescence 
intensity for each case are shown inside the corresponding panel. 
Table  2.  Specific Inhibition of mAb CIO Binding  by Chagasic Sera 
Source of blocking antibodies 
Percent inhibition  of binding 
mAb C10 
Titer  T.  cruzi  Sp2/0 + 
mAb M1/9 
Sp2/0 § 
Normal mouse serum  <10  0  0  0 
T.  cruzi-immune  mouse serum  10,500  30  18  0 
T.  cruzi-infected  mouse serum  325  60  42  0 
Normal human  serum  1  <10  0  0  0 
Normal human  serum 2  <10  0  0  0 
Chagasic patient  1  220  40  77  0 
Chagasic patient  2  180  45  73  0 
Chagasic patient  3  110  52  44  0 
Chagasic patient  4  240  51  83  0 
Chagasic patient  5  80  62  53  0 
mAb C10  supernatant  1,800  80  75  0 
Binding of mAbs C10 or M1/9.3.4.HL.2 (anti-murine  CD45) to T. cruzi or SP2/0 § membrane was studied by flow cytometry analysis. 1-2  x 
106 T. cruzi epimastigotes or 1-2  x  10  s Sp2/0 + cells were resuspended and incubated with 100 #1 of each sera diluted 1/10 in PBS with 2% BSA 
and 0.1% sodium azide for 1 h at 4~  After three washes with the same buffer, the parasites or cells were incubated with 10 #g/ml biotin-labded 
mAb C10 or mAb M1/9.3.4.HL2 for 30 rain at 4~  The parasites or cells were washed and incubated for 30 min at 4~  in the dark with streptavidin-PE 
or goat anti-rat IgFITC, respectively. The fluorescence  was analyzed in an EPICS cytofluorimeter. The titer shown refers to the antibody titer against 
T. cruzi determined by ELISA as described (19). 
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Figure 10.  Inhibition of human T cell proliferation by mAb C10 and 
Igs from chagasic sera. Human T cells were activated with 1/~g/ml PHA 
in the presence of the indicated concentrations of purified Ig from normal 
human serum (O), two chagasic sera (A and ,),  and mAb C10 (e) for 
72 h. Cell proliferation was estimated by the amount of [3H]thymidine 
incorporated during the last 4-16 h of culture. 
has  been  reported  (28-36).  This  immunosuppression  is 
thought to diminish the resistance of the host to the estab- 
lishment and dissemination of  the disease. However, the mo- 
lecular basis for this immunosuppression  is not well under- 
stood.  These effects have been attributed to impaired  Ib2 
production due to the presence of  suppressor cells: either mac- 
rophages (28-30) or T cells (31-35), or to T. cruz/immunosup- 
pressive factors (36). Another mechanism could be the poly- 
clonal activation of lymphocytes  that may alter the reactivity 
against foreign antigens causing the immune system to re- 
spond poorly to further antigenic challenge due to a state 
of refractoriness (4). The results shown in this manuscript 
add a new potential mechanism to explain this immmunosup- 
pression. The presence in &agaric sera of T. cruzi-specific 
antibodies with similar properties as mAb C10 could theo- 
reticaUy be able to suppress T and B cell activation like mAb 
C10 does in vitro and may account for the suppression of 
the immune response. Alternatively, they may indirectly con- 
tribute to the immunosuppression  by eliminating activated 
lymphocytes through complement-mediated killing. 
Recently, a mAb against another pathogen with similar 
functional properties to mAb C10 has been described (37). 
This antibody, specific  for a measles virus protein, crossreacts 
with a T lymphocyte subset also causing immunosuppres- 
sion. This crossreactivity has been also suggested to play a 
role in the etiology of measles-induced immunosuppression 
in vivo (37). 
The 28-kD antigen recognized by mAb C10 on T and B 
lymphocytes seems to represent a yet undescribed activation 
antigen at least in mice. This antigen appears late after acti- 
vation with several mitogenic activators and seems to be in- 
volved in the regulation of the late stages of lymphocyte 
proliferation. Among those, mAb C10 blocks II~2-dependent 
proliferation of T cells (Hern~ndez-Munatn et al., manuscript 
in  preparation).  A  somewhat similar  activation  antigen, 
CDw70, has been described in human T and B lymphocytes 
(38); this  antigen,  like mAb C10  antigen,  is  present  in 
T- and B-activated lymphocytes but absent in thymocytes (38) 
(Fig. 2 and data not shown). The described molecular mass 
of CDw70, detected by immunoblot techniques, is "~30 kD, 
similar  to  that of mAb C10  antigen. Furthermore, anti- 
CDw70 antibodies have inhibitory activity on lymphocyte 
proliferation like mAb C10. Recently, a 26-kD TAPA-1 an- 
tigen has been described in human T and B cells (39) that 
also shares some similarities with mAb C10 lymphocyte an- 
tigen. Experiments are in progress to further characterize the 
p28 antigen. 
In summary, our results show the existence of an antibody 
specific for T. cruzi  that is crossreactive with an activation 
antigen present on T and B lymphocytes. This may have im- 
plications in the understanding of the complex pathology of 
this disease. Our data suggest that T. cruzi presents antigens 
on its membrane that can induce crossreactive antibodies to 
the surface antigens of T. cruzi-activated  lymphocytes during 
the infection  altering  their functionality. 
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